Quick Read – Walmart’s eCommerce surged 26% and JNJ’s pharma sales grew 10%, yet JNJ’s lower 30x P/E and 2% yield offer more compelling value. – With consumer sentiment near recessionary lows, Walmart’s upper-income gains face a real stress test that JNJ’s pipeline and 64-year…
vidend streak do not. – Walmart (NYSE:WMT) and Johnson & Johnson (NYSE:JNJ) just delivered results that show two defensive giants pulling on very different levers. Walmart posted $175.68 billion in Q1 FY27 revenue with omnichannel firing on all cylinders
J&J leaned on its pharma pipeline to grow Q1 2026 sales 9.9%. Both beat estimates. The playbooks could hardly look more different.
Retail Flywheel Meets Pharma Firepower Walmart’s quarter was a story of stickiness turning into leverage. U.S. comp sales rose 4.1% ex-fuel on 3.0% transaction growth, and global eCommerce jumped 26%, now 23% of sales. Advertising climbed 37%, and marketplace sales surged nearly 50%, the best in ten quarters.